Answers are grounded in this paper and cite their sources.
The relative EGFR mutation abundance could predict benefit from EGFR-TKI treatment for advanced NSCLC.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: